Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

Most of the literature on safety and efficacy and YSML in DME is based on evaluation of best-corrected visual acuity (BCVA) and central macular thickness (CMT) outcomes after treatment. A summary of the data collected is reported in Table 1.

The mean follow-up of all the studies ranged between 2 and 16.6 months [29‐42]. Overall, a worsening of both BCVA and CMT was not observed in any of the cohorts evaluated [29‐42]. In particular, a significant CMT decrease and BCVA improvement in two thirds were demonstrated [29‐37] and in half of the studies [29, 30, 33, 36, 38, 40, 41], respectively, whereas a stabilization of these features was described in the remaining cases throughout the entire follow-up [31, 32, 34, 35, 37‐42].

No visible retinal or choroidal lesions were described in any studies on either fundus examination or fundus imaging [fundus autofluorescence (FAF), fluorescein angiography (FA) or color fundus photograph]. On optical coherence tomography (OCT), no integrity or reflectivity changes of the outer retina (external limiting membrane, inner segment/outer segment junction, RPE) were described. No side effects were reported [29‐42].

An interesting stratification of the data was done in two studies by Citirik et al., who allocated the study subjects into different groups according to their initial CMT: group 1 ranged between 250 and 300 μm, group 2 between 301 and 400 μm and group 3 had a baseline CMT > 401 μm [29, 30]. The results indicated that the anatomical severity of DME may affect the YSML outcome, with a statistically significant improvement of BCVA and CMT observed only in the group 1 patients with a baseline CMT < 300 μm. The cause of YSML lack of response in patients with severe anatomical disease is not known; however, it was speculated that severe edema could dilute and reduce the concentration of cytokines released by YSML-stimulated RPE cells that might be responsible for the beneficial effects of the treatment [29].

Another independent variable that was extensively found to affect the therapy outcome was the timing of response. Indeed, it was shown that the vast majority of patients with DME were characterized by a significant CMT shrinkage within the first 3 months of therapy and that from the 4th month onwards no further CMT reduction could be observed [43, 44] In other words, if no improvement is achieved within the first 4 months, waiting longer is unlikely to result in any significant beneficial YSML effect.

Kikushima et al. and Vujosevic et al. drew a comparison of morphologic and visual function safety parameters between YSML versus the subthreshold micropulse infrared (810 nm) laser, which is a widely adopted wavelength in published studies to test subthreshold laser efficacy [35, 45]. No significant differences were found in terms of either efficacy outcomes or safety profile between the two SLTs, suggesting the two lasers to be comparable in treating mild center involving DME [35, 45].

To date, there is great variability in the choice of laser power, titration, DC and pulse duration for DME eyes [31, 46]. A group of experts recently published the YSML consensus guideline settings for DME suggesting a DC of 5%, pulse duration 200 ms, spot size 150–200 μm with no spacing between spots and titration power of 50% of threshold power [11, 46].

Donati et al. evaluated efficacy and safety of morphologic and functional outcomes of diabetic patients affected by mild center involving DME treated with two different settings of yellow subthreshold laser: a fixed and a variable regimen delivered with the same DC (5%) [31]. The main considered outcomes were BCVA and CMT changes in both groups. Fixed regimen consisted of 100 μm spot size, 250 mW power and a variable number of confluent spots based on the center involving DME extension. Regarding the variable regimen, instead, micropulse laser power was selected starting with a 200-μm CW test burn in non-edematous areas outside the vascular arcades. The preferential starting power was 70 mW, slowly increased by 10–20 mW until a hardly visible burn was seen, at which point the laser was switched to micropulse mode multiplying the test burn power by 4 and keeping the spot size of 200 μm. Both YSML treatment regimens were found equally effective in terms of BCVA stabilization and center involving DME reduction [31].

To support the safety of YSML, Wells-Gray et al. performed an observational study investigating the integrity of individual cones after YSML treatment using high-resolution retinal imaging [47]. Cones that were evident before the treatment remained visible, whereas cones that were initially hidden by the DME became even more distinguishable after treatment. In addition, total retinal thickness displayed a statistically significant thinning in 50% of the patients, and no subject showed any sort of photoreceptor impairment after the therapy [47].

Optical coherence tomography angiography (OCTA) was also used to investigate parameters that could be potentially affected in DME patients after YSML treatment [41, 48]. The area of foveal avascular zone, number of microaneurysms (MAs), cyst area and presence of capillary network alterations were investigated within the superficial capillary plexus (SCP) and deep capillary plexus (DCP). The most peculiar finding of this study was the early decrease of MA number within the DCP, considered a hallmark of DR [49]. Leaking MAs are believed to be one of the main causes of DME development; therefore, their reduction within the DCP may ultimately lead to an inner nuclear layer (INL) thickness decrease and consequently DME shrinkage [50, 51].

Of note, YSML is not directly targeted to MAs, as it is instead the modified conventional ETDRS laser treatment, which determines MA clotting. Indeed, the RPE is considered the main site of action of YSML, but the exact mechanism leading to MA closure is still unknown [51].

Two relatively recent papers assessing retinal thickness changes after repeated YSML sessions in DR patients demonstrated an important INL thickness reduction as a result of Müller cell (MC) downregulation and return to normal size [40, 52].

Furthermore, Midena et al. demonstrated a marked reduction of diabetes-induced glial fibrillary acidic protein (GFAP), an important biomarker of MCs activity, following YSML [17]. The association of all these molecular findings suggests that YSML induces morpho-functional recovery of MCs with a substantial reduction of their inflammatory pathologic biomarkers [17, 52].

Anti-VEGF injections have emerged as the first-choice treatment for DME [53]. As widely demonstrated in clinical trials and real-life studies, protracted series of anti-VEGF injections are proven to efficiently manage DME [53]. However, the cost of recurrent injections and ophthalmologic check-ups imposes a significant economic burden on these patients and seriously hinders provision of optimal treatment [54].

Currently, in real-life routine practice, ophthalmologists may also consider other choices for DME management, including YSML.

Several studies in the literature have compared YSML with anti-VEGF therapy for DME. A summary of the data collected is reported in Table 2.

The mean follow-up of the studies shown ranged between 6 and 24 months [55‐64]. Most of the studies reported indicated a common positive result for the usefulness of YSML, which appeared to have complimentary effects to the anti-VEGF therapy [55‐64]. Their combined use was demonstrated, in fact, to significantly reduce the number of anti-VEGF injections while preserving or even improving morpho-functional outcomes. BCVA improvement and a CMT decrease were illustrated in two thirds [55, 56, 58‐61, 63] and in half of the studies considered [55, 58‐61], respectively, and a stabilization of these features was described in the remaining cases throughout the entire follow-up [56, 57, 62‐64].

Of note, only two studies reported no significant differences within the cohorts treated with anti-VEGF therapy and anti-VEGF + YSML in terms of number of injections needed [62, 64].

All these studies highlighted the advantages of performing YSML in mild DME cases, including the easy administration, laser treatment management and lower costs of the procedure [55‐64].

The efficacy of YSML over anti-VEGF therapy was also evaluated in terms of OCTA changes in a retrospective analysis carried out by Karasu et al. [65]. Data of 44 eyes of 44 patients with DME refractory to anti-VEGF were reported in a 6-month single-center follow-up study. A significant decrease (p < 0.05) occurred in the SCP, choriocapillaris and DCP, which caused a substantial decrease in vessel densities. In parallel, BCVA improved and CMT decreased significantly [65].

Laser photocoagulation was suggested as preferential therapy for DME after ETDRS, much before the anti-VEGF era [66]. Contrast sensitivity reduction, accidental foveal impairment, poor color vision and expansion of macular scars were common complications of laser photocoagulation, which led this procedure to take a backseat over the years [67].

The efficacy and safety of YSML were compared to conventional retinal laser photocoagulation by Chhablani et al. who conducted a 3-month prospective randomized study including 30 eyes of 20 patients who received either YSML or standard CW laser [67]. All patients underwent microperimetry, thickness measurements and visual acuity examinations. While both treatment arms achieved a stabilization of BCVA, the main differences between the two groups involved retinal volume and sensitivity. These two parameters were demonstrated to be heavily and negatively impaired by CW therapy, whereas positively preserved when treated with YSML [67].

Li et al. quantitatively investigated the combined effect of YSML with panretinal laser photocoagulation (PRP) on 86 eyes of 86 patients previously diagnosed with severe non-proliferative diabetic retinopathy (NPDR) with a center involving DME [68]. Several OCTA parameters, including foveal avascular zone (FAZ), capillary density (CD), CMT, choriocapillary flow area (ChF) and BCVA, were evaluated during a 6-month observational retrospective study. Overall, BCVA remained stable throughout the entire follow-up. CMT, macular edema, blood flow and capillary density were characterized by a decreasing trend, whereas FAZ tended to increase during the 6-month period [68].

A limitation of these studies includes the relatively small sample sizes and short-term follow-ups unable to highlight the effects of DME recurrences. In addition, visual function examinations such as visual field test were not performed. From this perspective, further prospective studies with more patients would help to better understand the compared effect of YSML with conventional laser.

Application of YSML in patients who previously underwent pars plana vitrectomy (PPV) for tractional DME was explored by Bonfiglio et al. [69]. They reported data of a consecutive comparative prospective study on 95 eyes of 95 patients in which 54 eyes were treated 6 months after PPV with YSML and 41 eyes were assigned to the control group only for observation. In the treatment group, mean BCVA increased and CMT decreased in parallel more significantly than in the control group. In addition, vessel densities evaluated with OCTA in the SCP and DCP were substantially higher and FAZ significantly smaller in the YSML group. No adverse effects were described in YSML patients [69].

To assess the efficacy of YSML in chronic CSC, special focus was placed on the SRF and CMT reduction and BCVA variation after treatment. A summary of the data collected is reported in Table 3.

Overall, a BCVA improvement was reported [73‐91], except for one study displaying a visual acuity stabilization [92].

All the studies that explored a SRF variation showed a reduction of the fluid [73‐92]. No visible retinal or choroidal lesions were described in any study, and no side effects were reported [73‐92]. Wood et al. hypothesized that, since laser energy of visible wavelengths is mainly absorbed by the RPE, the efficacy of YSML could be related to RPE cell vitality and trophism [9].

Chen et al. further subcategorized the cohort of patients based on three phenotypes classified according to FA: (1) focal point of iuxtafoveal leakage with no RPE atrophy, (2) focal point of iuxtafoveal leakage with RPE atrophy and (3) diffuse RPE impairment with indistinct source of iuxtafoveal leakage. They reported an increasing trend of fluid reabsorption and decreasing SRF recurrence in patients with limited RPE atrophy and focal leakage [93].

Other anatomic features have been investigated as predictors of higher YSML effectiveness.

In particular, Kiraly et al. demonstrated the amount of SRF to be an important biomarker in predicting treatment response by observing worse outcomes in cases with greater SRF [82]. They also investigated the role of pigment epithelium detachments (PEDs), concluding that wider PEDs correlated with poor response to YSML [82].

Several OCT parameters were demonstrated to influence the YSML response.

Altinel et al. observed 39 eyes of 39 patients for 24 months, focusing on the ellipsoid zone (EZ) band integrity and analyzing its correlation with YSML success status [94]. The eyes were allocated into three groups: complete remission, partial remission and failure. Baseline EZ was found significantly intact in 71.4% of eyes in the complete remission group, and these rates were progressively inferior in the partial remission and failure groups, with 38.5% and 25%, respectively [94].

Hyperreflective dots were also found in all the retinal layers, and subretinal fibrinous exudates were seen more commonly in the failure group than in the complete remission group (p > 0.05) [94]. These findings suggest that hyperreflective dots may help predict the need for early YSML treatment.

There is only one report in the literature showing the use of 577-nm YSML to successfully treat a patient with chronic CSC with subretinal fibrin deposition with complete subretinal fluid and fibrin reabsorption and no visible retinal damage [95].

A representative case of chronic CSC successfully treated with YSML is shown in Fig. 1.

The PLACE Trial confirmed photodynamic therapy (PDT) to be superior to high-density subthreshold laser (HDSL) treatment for chronic CSC in terms of patients’ percentage with complete SRF resorption, BCVA increase and higher mean retinal sensitivity increase on microperimetry [96]. HDSL treatment protocol consisted of a DC of 5%, spot size of 125 µm, power starting from 1800 mW with lowering of 300 mW if any retinal discoloration was visible and pulse duration of 200 ms. PDT consisted of half-dose verteporfin (3 mg/m²) infused over 10 min followed by laser activation for 83 s [97].

Considering that PDT is an invasive procedure that can rarely carry risks of collateral retinal damage, several authors suggest YSML as a competitive alternative for chronic CSC [75, 97]. Moreover, in the last 2 years there has been a verteporfin shortage worldwide that still represents a problem in many countries [98].

PDT and YSML have different mechanisms of action. While YSML targets the RPE, the treatment effect of PDT is believed to be the result of remodeling of the choroidal vascular endothelium through the formation of free radicals after photoactivation, resulting in occlusion, thrombosis and choroidal hypoperfusion in the treated areas [99].

Roca et al. treated leakage sites identified by FA and/or ICGA in a cohort of 92 eyes followed up for 12 months with either YSML or PDT. The first consisted of a DC of 5%, spot sizes from 100 to 200 µm, power from 320 to 660 mW and pulse duration of 200 ms; the latter consisted in half-dose verteporfin (3 mg/m²) infused over 10 min, followed by laser activation for 83 s. The authors described a significant CMT decrease from baseline in both YSML and PDT groups [100]. BCVA paralleled this improvement only in patients treated with YSML with a gain of ≥ 3 lines. Contrarily, in the PDT group after the 12-month follow-up, only 19% of eyes had such a visual acuity increase, with the vast majority (73%) recuperating no more that two lines from baseline BCVA. Notably, no adverse events attributable to the YSML were observed, whereas one eye within the half-dose PDT group developed choroidal neovascularization 4 weeks after the treatment and was treated with three intravitreal bevacizumab injections [100].

Ntomoka et al. retrospectively assessed 45 eyes of 39 patients who underwent either one of the two treatments with a minimum follow-up of 6 months [101]. PDT was performed over areas of choroidal hyper-permeability on ICGA by injecting a normal dose of verteporfin infused over 8 min followed by laser activation for 83 s. YSML was carried out in confluent spots directed to areas of focal leakage in the earliest phase of FA with a DC of 5%, spot size of 100 µm, pulse duration of 200 ms and 30% threshold power. The group treated with YSML demonstrated a significantly greater increase in BCVA compared to PDT [101]. The trend was confirmed anatomically, with a CMT decrease significantly higher in the YSML group as well. In addition, 13 (59%) eyes treated with subthreshold laser showed complete SRF reabsorption compared to only 5 (21%) in the PDT cohort [101].

In a study with a long-term follow-up, Scholz et al. made a comparison by retrospectively analyzing 100 patients with a mean follow-up of 2.6 years (SD ± 3.3), of which 42 received YSML while the rest were treated with PDT [102]. Hyperfluorescent areas on mid-phase ICGA and the corresponding “hot spots” on mid-phase FA were treated. YSML treatment protocol consisted of a DC of 5%, spot size of 160 µm, pulse duration of 200 ms, 50% threshold power and PDT consisting of half-dose verteporfin (3 mg/m²) infused over 10 min followed by laser activation for 83 s. Results observed showed similar anatomic outcomes with comparable CMT decrease (p < 0.05) and SRF resorption (p > 0.05) within the two treatment arms; BCVA, instead, improved more in the YSML group (p > 0.05). They noted a significant difference between the two groups in treatment response regarding the duration, more or less than 1 year, of the disease. Indeed, a significant higher number of patients with a disease duration < 1 year showed treatment response to YSML (92% vs. 58%). Another OCT variable demonstrated to have an impact on both treatment responses was central retinal thickness (CRT): non-responders showed a statistically significant lower CRT at baseline compared to responders (337 ± 81 μm vs. 442 ± 131 μm). Regarding safety, only the PDT group displayed side effects: one patient developed CNV, and one patient suffered from a moderate allergic reaction to verteporfin with tachycardia, dyspnea, flushing and hypotension [102].

Altinel et al. retrospectively compared 52 eyes of 46 patients over 8.42 (± 3.34 SD) months [92]. They found that the YSML group was characterized by longer SRF resolution duration and a slower trend of BCVA improvement compared to the fellow group. EZ band integrity was explored as well, with higher SRF resolution rates observed in both treatment arms when EZ was intact [92].

Ozmert et al. retrospectively evaluated 33 eyes of 30 patients during a 12-month follow-up [103]. Their results reached similar findings: mean BCVA (p > 0.05), CMT and SRF (p < 0.05) outcomes improved significantly with YSML treatment, consisting of a DC of 5%, spot size of 160 µm, pulse duration of 200 ms and 50% threshold power [103].

Ho et al. investigated alterations in choriocapillaris blood flow with OCTA and choroidal volume with en-face OCT [104]. Eighteen patients were randomized into YSML and PDT groups. YSML was set with a DC of 5%, spot size of 200 µm, pulse duration of 200 ms and power of 340–400 mW, whereas PDT was performed with half-dose verteporfin (3 mg/m²) infused over 10 min followed by laser activation for 83 s. Results were extremely positive: flow deficit areas with suspected choriocapillaris hypoperfusion were found in all CSC cases at baseline, and a progressive reduction of such areas was found in both YSML and PDT groups (p < 0.05), with the latter showing better results. Mean choroidal volume decreased as well at all time points (1, 3 and 6 months), but only in the PDT arm [104].

Van Rijssen et al. prospectively analyzed 29 eyes of 29 patients from the PLACE trial cohort for 8 weeks to assess whether choroidal vascularity index (CVI) changes could be responsible for therapeutic efficacy of both PDT and YSML [105]. No significant correlations were demonstrated between CVI and the two treatment options, leading the authors to conclude that any CVI change may not be primarily responsible for the treatment effect [105].

The efficacy of YSML was also compared to conventional laser treatment.

Sun et al. carried out a prospective, double-masked, 12-week trial, randomizing 88 patients with a diagnosis of chronic CSC to one of the two lasers [106]. At the end of follow-up, YSML demonstrated non-inferiority to CW laser regarding BCVA improvement. In contrast, anatomical outcomes appeared to be more prominent in the cohort treated with threshold laser, which displayed a proportion of patients with complete SRF reabsorption of 81.82% compared to 63.63% of YSML [106].

Maruko et al. retrospectively investigated 28 patients over 3.4 months in the CW laser group and 2.2 months in the YSML group [107]. BCVA showed no improvement compared to baseline, whereas SRF resolution outcomes were equivalent between the two lasers (66% and 64% in CW laser and YSML, respectively). Importantly, despite comparable therapeutic effects, CW laser treatment resulted in RPE damage at the site of laser delivery in all eyes treated, while only one eye that underwent YSML developed some sort of RPE modification on FAF [107].

Oral mineralocorticoid receptor inhibitors (MRIs) such as eplerenone and spironolactone were found to be associated with SRF resolution, choroidal thickening decrease and BCVA improvement in the short term [108].

However, Lotery et al., running a randomized, double-blind, placebo-controlled trial over a 12-month follow-up on 114 patients, assigned each patient to receive either eplerenone (57) or placebo (57) and found that MRI was not superior to placebo in BCVA improvement [109].

A few other studies in the literature compared eplerenone to YSML effectiveness.

Toto et al. retrospectively enrolled 36 eyes of 30 patients into subthreshold and eplerenone groups and followed them up for 3 months [110]. Mean BCVA, CMT and SRF improved significantly by the end of the follow-up (p < 0.001) in both cohorts. In particular, 55.6% and 66.7% of patients showed a complete reabsorption of SRF over the period of interest in the YSML and eplerenone groups, respectively [110].

Vignesh et al. retrospectively evaluated 48 eyes over a median follow-up of 8 months in YSL and 4.5 months in the eplerenone treatment arm [111]. Complete SRF resorption was observed in 12/28 (42.8%) eyes in YSML, a much higher proportion compared to eplerenone (4/20, 20%). BVCA paralleled the anatomical outcomes, showing a greater improvement in YSML versus eplerenone group (0.14 vs. 0.05 logMAR) [111].

No paper compared YSML's efficacy to spironolactone or evaluated its effects on CSC.

In the last decades, anti- VEGF injections dramatically decreased the incidence of vision loss due to CNV in neovascular age-related macular degeneration (AMD) [112]. Contrarily, no therapy is available to prevent dry AMD from progressing into its latest stage, geographic atrophy (GA) [113]. Reticular pseudodrusen (RPDs) are associated with an increased progression to both forms of late AMD [114, 115]. In this light, a therapy that targets RPD progression could be pivotal for AMD management. Considering that the RPE dysfunction was suggested as the main causative element in RPD pathogenesis, a subthreshold laser that preserves and stimulates RPE function could play a crucial role [116, 117].

Querques et al. prospectively enrolled 20 eyes of 20 patients with a RPD finding secondary to a diagnosis of dry AMD and treated them with YSLT, following them up over a 3-month period [118]. No changes in BCVA were observed from baseline. YSML-treated areas did not display any sort of worsening in macular sensitivity, whereas RPD distribution and concentration appeared to be affected (p < 0.05). In particular, a significant increase of stage-1 RPDs [characterized by a diffuse deposition of hyperreflective material between the RPE and the inner/outer segments (IS/OS) boundary] was observed (p < 0.05) and associated with a decrease of stage 3 RPDs (featured by a thicker and conical appearance of deposited material passing through the IS/OS boundary). A statistically significant association was also found between RPD regression and ONL thickness increase (p < 0.05) [118].

Huang et al. focused their research on evaluating long-term outcomes of YSML on drusenoid PEDs [119]. A total of 21 eyes of 16 patients were consecutively included and followed up for a mean of 25.3 (SD ± 12.6) months and categorized in two groups based on presence (6 eyes) or absence (15 eyes) of drusenoid PED collapse after YSML treatment. Height, area and volume of dPEDs were positively correlated with the collapse, suggesting that larger lesions are more likely to collapse after YSML treatment. Moreover, the collapse group showed faster growth and regression rates of dPEDs compared to the natural course of these features, therefore reducing the RPE separation from the underlying Bruch’s membrane/choriocapillaris complex and consequently mitigating the RPE damage. More importantly, at the end of the follow-up, BCVA was stable compared to baseline and similar within the two groups, suggesting that YSML could alleviate not only the natural course of the disease but also its related vision impairment [119].

Further prospective studies with larger sample size are needed to further confirm these data.

Pseudophakic cystoid macular edema (PCME), also known as Irvine-Gass syndrome, is a major cause of unexpected postoperative vision loss [120, 121]. Surgical insults along with postoperative inflammation are widely shown to be the important risk factors for this condition, which commonly tends to resolve spontaneously [122]. However, for chronic presentations treatment is often mandatory, requiring steroidal or non-steroidal anti-inflammatory (NSAI) drugs or even anti-VEGFs or steroid intravitreal injections [123, 124].

Verdina et al. retrospectively included ten eyes of ten patients with refractory PCME to standard treatments, namely NSAI eyedrops, topical steroids, oral indomethacin, sub-Tenon triamcinolone injections and dexamethasone intravitreal implant [125, 126]. All underwent YSML and were followed up for 6 months. Five cases occurred after uncomplicated cataract surgery, two cases after complicated cataract surgery with posterior capsule rupture and three cases subsequent to retinal detachment. At the end of the follow-up, BCVA had improved significantly from baseline. Anatomic restoration was also demonstrated with complete resorption of cystoid macular edema and a statistically significant CMT reduction (p =  < 0.005) [125, 126].

A representative case of postsurgical CME successfully managed with a single YSML session in a patient operated on for a rhegmatogenous retinal detachment is shown in Fig. 2.

Radiation retinopathy is a progressive and chronic vasculopathy secondary to exposure to radiation. Current treatment includes thermal laser photocoagulation, intravitreal anti-VEGF and steroid injections, and hyperbaric oxygen [127]. Despite treatments patients often may have progressive visual impairment secondary to ischemic retinal damage. Wong et al. reported a case of a 60-year-old man who developed retinopathy in his left eye 23 years after radiotherapy for nasopharyngeal carcinoma treated with YSML [128]. Baseline BCVA was 20/40, and FA showed macular leak compatible with CME, which was confirmed on OCT. Ten months after one single treatment, BCVA improved to 20/20, and OCT examination demonstrated complete reduction of the cystoid macular edema [128].

Several treatment modalities for branch retinal vein occlusion (BRVO) have been proposed over the years; among them, anti-VEGF is recognized as the treatment of choice for BRVO-induced CME [129].

Terashima et al. retrospectively enrolled 46 eyes of 46 patients with BRVO and allocated them to two groups: the first received intravitreal ranibizumab (IVR) + YSML, whereas the second underwent IVR monotherapy [130]. BCVA and CMT improved in both groups, and results did not differ significantly between the two. However, the number of intravitreal injections decreased significantly in the IVR + YSML group compared to the IVR-only cohort (2.3 ± 0.9 vs. 1.9 ± 0.9) at the end of the 6-month follow-up [130].

Type 1 macular telangiectasia (MacTel) is an aneurysmal telangiectasia, most commonly unilateral and typically found in the temporal half of the macula. It commonly occurs in middle-aged males, and it is thought to be a variant of Coats’ disease [131]. Therapeutic options consist of laser photocoagulation, intravitreal injections of steroids or anti-VEGF agents [132]. Kang et al. reported a case of a 54-year-old man with type 1 MacTel in the left eye [133]. BCVA was 20/800 at baseline, and spectral domain (SD)-OCT showed severe CME, for which he underwent two ineffective intravitreal injections of bevacizumab before receiving three YSML sessions. One month after the last treatment, SD-OCT demonstrated complete CME resorption and absence of any macular damage. However, after 1 year the treated area showed focal atrophic changes, which the authors claimed to potentially be associated with the chronic CME but they could not exclude that it was triggered by repeated YSLT. Nevertheless, at 3-year follow-up BCVA still improved to 20/40 in the treated eye [133].